In intensive care units around the world, a quiet inequity persists at the intersection of biology and institutional habit: sepsis patients receive antibiotic doses calibrated to a generalized body that does not exist. A new editorial by Dr. Helena Barrasa, Dr. Goiatz Balziskueta, and Prof. Jordi Rello argues that biological sex and gender bias together distort treatment outcomes — leaving women vulnerable to toxicity and men to underdosing. The science of precision medicine has long offered a path forward, yet the will to walk it has lagged behind the knowledge that demands it.
Experts call for sex-aware sepsis treatment protocols to address dosing disparities
Cobertura Relacionada
Hundreds of thousands of UK students received GCSE results showing overall grade improvements in 2025, with the gender g…
The Straits Times · Aug 20 Ebola spreads beyond Congo epicentre, overwhelming treatment capacityEbola cases in DRC are accelerating outside the initial Ituri epicenter, with North Kivu and Haut-Uélé provinces experie…
Science Daily · Aug 20 1,000+ genetic switches explain why women face higher autoimmune disease riskResearchers identified over 1,000 genetic switches that function differently in male and female immune cells, explaining…
News-Medical · Aug 20 Brain's Local Wiring May Buffer Cognitive Decline in Older AdultsUSC researchers found that white matter integrity helps protect cognitive function in older adults by compensating for g…
Sesgo y Encuadre
Article advocates for sex-aware sepsis protocols, emphasizing women's overexposure risks and men's underdosing issues, with significant focus on gender inequities in care delivery.
Problem-solution framing with emphasis on health equity disparities. The article frames standardized dosing as a systemic failure requiring urgent protocol reform, positioning sex/gender-aware medicine as the corrective solution.
Impacto Geopolítico
Medical experts advocate sex-aware sepsis treatment protocols to address pharmacokinetic disparities and gender inequities in antibiotic dosing, affecting global ICU care standards.
Shift toward evidence-based medicine challenging standardized protocols; medical institutions gaining influence through advocacy for personalized treatment; potential realignment of pharmaceutical dosing standards globally.
Similar to the 1990s-2000s movement recognizing sex-based differences in cardiovascular disease treatment, which eventually led to FDA guidance on sex-specific drug testing and dosing.
Lente Económico
Medical experts advocate for sex-aware sepsis treatment protocols to address dosing disparities, potentially reducing adverse drug reactions in women and treatment failures in young men, with implications for healthcare costs and clinical outcomes.
Patients may experience improved treatment outcomes and reduced adverse drug reactions through personalized dosing; however, implementation costs could increase healthcare expenses. Women and young men with sepsis would benefit from more tailored treatment protocols, potentially reducing hospitalizations and mortality-related economic losses.
Regulatory bodies (FDA, EMA) may require sex-stratified pharmacokinetic data in drug trials and approval processes. Healthcare systems may need to update clinical protocols and invest in personalized medicine infrastructure. Potential mandates for gender-disaggregated health outcome reporting and equity audits in emergency departments. Insurance reimbursement models may shift to incentivize precision dosing protocols.